Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.
Cisplatin is a highly-effective and widely-used chemotherapeutic agent that causes ototoxicity in many patients. Pharmacogenomic studies of key genes controlling drug biotransformation identified variants in thiopurine methyltransferase (TPMT) as predictors of cisplatin-induced ototoxicity, although...
Main Authors: | Amit P Bhavsar, Erandika P Gunaretnam, Yuling Li, Jafar S Hasbullah, Bruce C Carleton, Colin J D Ross |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5391095?pdf=render |
Similar Items
-
Detection of Thiopurine S-Methyltransferase (TPMT) Polymorphisms TPMT*3A, TPMT*3B and TPMT*3C in Children with Acute Lymphoblastic Leukemia
by: Nawar S. Mohammed, et al.
Published: (2018-12-01) -
P044: Pharmacogenetic profile for NUDT15 and TPMT in a Peruvian population with pediatric acute lymphoblastic leukemia
by: Jeny Bazalar-Montoya, et al.
Published: (2023-01-01) -
Diabetes-induced cellular changes in the inner ear
by: Ahmed Gedawy, et al.
Published: (2024-01-01) -
Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
by: Angela Wu, et al.
Published: (2023-09-01) -
Positive TPMT genotype-phenotype correlation underscores importance of TPMT genotyping for personalized thiopurine dosing
by: Hui-min, Neoh, et al.
Published: (2012)